Mr. Gemignani will join our Bluejay’s Board of Directors upon the closing of this offering. Mr. Gemignani has served as EVP, Chief Financial Officer of Acacia Pharma Group plc, a hospital pharmaceutical company since January 2020. Prior to Acacia Pharma, Mr. Gemignani served as CFO of Synergy Pharmaceuticals Inc. from 2017 to 2019 where he successfully led the sale of this Nasdaq-listed company’s assets to Bausch Health.
Synergy Pharmaceuticals Inc. filed a petition in the United States Bankruptcy Court for the Southern District of New York in December 2018 under Chapter 11 of the U.S. Bankruptcy Code. Previously, Mr. Gemignani served as CEO and CFO of Biodel Inc., overseeing business and strategic planning, operations and financing activities of the company. Prior to this, Mr. Gemignani served in senior and executive financial and operational roles with multiple public and private companies including, Prudential Financial, Gentium, Novartis and Wyeth. Mr. Gemignani started his career at Arthur Andersen & Co. We believe that Mr. Gemignani is well qualified to serve on our board of directors due to his extensive public company experience, as well as his accounting and financial experience.
Ms. Dey has been a member of Bluejay’s Board of Directors since 2015. She co-founded Bluejay Diagnostics in 2015 and LMBRI, a management consulting company focused on the launch and marketing of medical products in the US, Japan and India, in 2008. Ms. Dey served as LMBRI’s President and CEO since 2008 and is a Board member of Laminar Pharma, Inc. Prior to LMBRI, she spent more than 15 years in healthcare consulting. In these roles, she oversaw healthcare and life sciences product development, sales and marketing, and general management for more than 12 years. Ms. Dey holds a Master’s degree in Mathematics from the State University of Mari El Republic, Russia.
Mr. Dey co-founded Bluejay Diagnostics in 2015, after co-founding Lana Management & Business Research International (LMBRI) in 2007. LMBRI, which became inactive in 2017, was a management consulting company focused on the launch and marketing of medical products in the US, Japan and EU.
Mr. Dey spent about eight years at LMBRI, consulting with companies such as Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), and Fuji Chemicals. Prior to this, he held executive positions at several firms. From 2005–07, he was Vice President of Business Development and Market for Definines, AG (acquired by AstraZeneca). From 2001–05, he was Head of Business Development, Western US, at IMPATH, Inc. Here, he handled three business units and the introduction of a new product, Her2neu Diagnostics, for the treatment of breast cancer, with Herceptin. He was also Chief Business Officer at Genmethrax, Inc; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis).
Mr. Dey is a Bachelor of Science and has a master’s degree in Biochemistry from Visva-Bharati University in India and PhD in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also holds a Master of Business Administration degree (Fulbright Scholarship) from the University of Cambridge.
Mr. Zeidman has served on the Board of Directors since May 2021. He is Chairman of WoodRock & Co., an investment banking service business, Chairman and CEO of Good Works Acquisition Corp., and Chairman of Good Works II Acquisition Corp (both publicly held SPACs). Mr. Zeidman also served as Chairman of Gordian Group LLC, a US-based investment bank specializing in board level advice in complex, distressed, or “story” financial matters.
Mr. Zeidman, Chairman Emeritus of the United States Holocaust Memorial Council, was appointed by President George W. Bush in March 2002 and served in that position during 2002–10. A prominent Houston-based business and civic leader, Mr. Zeidman is also Chairman Emeritus of the University of Texas Health Science System Houston. He is former National Chairman of the Development Corp of Israel Campaign (Israel Bonds) and served on the Board of the National World War II Museum.
Mr. Zeidman was former CEO, President, and Chairman of Seitel, Inc., a Houston-based onshore seismic data provider, and played a key role in its successful turnaround. He served as Lead Director of Straight Path Communications, Inc. until its sale to Verizon in 2018. He was Director of REMA, a division of NRG Corp.; serves on the board of Prosperity Bank; and was formerly Restructuring Officer of TransMeridian Exploration Inc. and Chief Bankruptcy Trustee of AremisSoft Corp. He was Chairman of the Board and CEO of Unibar Corporation, the largest domestic independent drilling fluid company, until its sale to Anchor Drilling Fluids in 1992. Mr. Zeidman holds a Bachelor’s degree from Washington University in St. Louis and a Master of Business Administration from New York University.
Mr. Chase has served on Bluejay’s Board of Directors since 2017. He has been a member of the Board of Directors at Merchants Bank and Merchants Bancshares, Inc., in South Burlington. VT, from 2015 through 2017. Mr. Chase was Chairman of the Board of NUVO Bank and Trust Company of Springfield, Massachusetts, since its inception in 2008 through 2015.
He served as President and Chief Executive Officer, Vice Chairman, and Director of Westbank Corporation and its wholly owned subsidiary, Westbank, from 1988 to 2007. He is engaged in several commercial real estate, farming, and ranching activities, besides holding many civic roles. He is Chairman of the Board of Trustees for the Eastern States Exposition in West Springfield, MA, and Trustee of the Big E Trust. Mr. Chase is also Commissioner of the Board of Public Safety for the City of West Springfield, MA, and member of the Massachusetts Board of Agriculture.
Mr. Chase is a veteran of the US Army, having served in the combat in Vietnam from 1967 through 1969. He graduated with honors from Western New England University with a Bachelor of Science degree in Accounting.
Mr. Wurth has served as Chairman of the Board of Bluejay Diagnostics since 2017. He has been a private investor since 2016; Chief Executive Officer and Director of Good Works II Acquisition Corp. since February 2021; and Co-Chairman of Good Works Acquisition Corp. since October 2020. Mr. Wurth led major businesses in JP Morgan Asset Management during his nearly 20 years at JP Morgan from 1997 to 2016.
Mr. Wurth was Chief Executive Officer of Alternative Investments in Asset Management and Chief Executive Officer of JP Morgan’s International Private Bank, where he led the expansion of the franchise in Asia, Latin America, and Europe while being based in New York, Hong Kong, and London. Since leaving JP Morgan, Mr. Wurth has invested in and helped lead several private companies; of these, he is Chairman of the Board at Standard Power and Vestrata, and a Board member at Triax Technologies.
Before joining JP Morgan, Mr. Wurth practiced law at New York-based firm Skadden, Arps, Slate, Meagher & Flom from 1992–95 and served as General Counsel in former US Senator Robert Dole’s 1996 presidential campaign. Mr. Wurth holds a Bachelor of Arts degree from the University of Notre Dame and JD from the University of Virginia School of Law.
Bluejay Diagnostics, Inc. is developing easy-to-use, near patient medical diagnostics tests.